According to a news release in BioPharma Reporter, Novo Nordisk, a Danish pharmaceutical company, is set to establish a new AI research hub in London’s Kings Cross Knowledge Quarter.

This initiative involves renting office space and moving in early 2024. The hub will focus on innovative digital solutions, housing about 40 employees from the company’s R&D and IT divisions. It aims to leverage AI in developing new drug candidates.

The Knowledge Quarter is a hub for science and technology firms and institutes, facilitating collaboration with leading entities in AI, data science, and engineering. This move coincides with Novo Nordisk’s success in weight-loss drugs like Ozempic and Wegovy, despite supply shortages. The company is also working on an oral version of Wegovy and exploring AI-based obesity prevention strategies.